3626 results for «301»
3626 results
Most impactful trials in structural heart disease 2024/2025
30 Sep 2025 – From PCR Gulf Valves 2025
Delve into the most impactful structural heart disease trials shaping 2024 and 2025. This session addresses current dilemmas in TAVI, including early intervention and management of small annuli, evaluates evidence for transcatheter mitral and tricuspid valve repair, and identifies evidence gaps relevant to the region, providing...
Expanding horizons with balloon-expandable TAVI - LIVE Case
12 Sep 2025 – From PCR Rio Valves 2025
A 76-year-old male with a history of abdominal and iliac stent grafts (2022), severe COPD, prostate cancer, and gastric ulcer presented with symptomatic severe aortic stenosis. CT and echocardiography showed a calcified bicuspid aortic valve with preserved LV function.
A 24.5 mm Myval valve was implanted without...
Stent failure - LIVE Case
11 Oct 2025 – From AICT-AsiaPCR 2025
This educational session presents a live case from Apollo Hospitals, Chennai, focusing on stent failure management. It emphasizes the critical role of imaging in optimizing treatment for in-stent restenosis, discusses essential lesion preparation tools, and reviews various therapeutic options to improve patient care.
LIVE Educational Case from...
The PASCAL IID Registry: A prospective registry for transcatheter edge-to-edge repair in prohibitive risk patients with degenerative mitral regurgitation and complex mitral valve anatomy
17 Sep 2022
Alex Sticchi provides his take on the PASCAL IID Registry and an initial comparison with the CLASP IID. The trial was presented by Jörg Hausleiter during TCT Congress 2022.
Author
Long-term beta-blocker treatment after acute myocardial infarction and preserved left ventricular ejection fraction: The REDUCE-AMI Trial
07 Apr 2024
REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.
Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...
Author
Author
SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk
07 Nov 2021
Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...
Author
Author
